Cooley LLP

United Statescooley.com

Cooley LLP is an international law firm that advises companies, investors, and boards on corporate, regulatory, and litigation matters. The firm’s practice covers mergers and acquisitions, capital markets, private financings, licensing and collaborations, intellectual property counseling and enforcement, antitrust, employment, investigations, and complex disputes. Cooley serves clients across the innovation economy, with notable depth in technology, life sciences, healthcare, and venture capital. The firm operates across the United States, Europe, and Asia.

For chemical and life sciences stakeholders, Cooley provides counsel on transactions, IP strategy and protection, product and safety regulation, FDA- and EMA-related matters, supply and manufacturing agreements, data and privacy issues, corporate governance, and cross‑border deal execution. Its experience spans public and private company work, from early-stage financings through IPOs and post‑market compliance, as well as strategic M&A and partnerships involving biotech, pharma, medical devices, diagnostics, and specialty materials companies.

Latest news on Cooley

27 April 2026
Lilly to acquire Ajax Therapeutics for AJ1‑11095, a first‑in‑class Type II JAK2 inhibitor

Lead program in Phase 1; POC data due late 2026. Designed to deliver deeper, more durable responses than current Type I JAK2 therapies. Deal may pay up to $2.3B, subject to closing.

9 December 2025
Lilly Completes Acquisition of Adverum

Lilly's tender offer for Adverum shares expired, with 64% tendered. Acquisition completion expected Dec. 9, 2025. Legal and financial advisors involved.